Medicare Oncology Payment Program Could Pressure Part D Prices, Industry Says
This article was originally published in The Pink Sheet Daily
Executive Summary
A new Oncology Payment Model for Medicare will test episode-of-care payment for chemotherapy and offer incentives for keeping costs low, but biopharma firms are concerned that inclusion of Part D-covered cancer drugs in the cost measurement will intensify pressure on prices.
You may also be interested in...
Off-Label Communication Principles From PhRMA, BIO Aim For Reg Changes
Manufacturer communications with providers and payers could include real-world evidence and pharmacoeconomic information, associations urge.
Medicare Spending Forecast For Leqembi Reflects CMS Angst About Alzheimer’s Drug Costs
The agency’s projection that Medicare will spend $3.5bn on Leqembi in 2025 is nearly three times the level of sales that marketer Eisai is expecting for the drug in North and South America combined in its fiscal year 2026.
Biosimilar Substitution In Medicare Part D Formularies Mid-Year Established In Final Rule
Policy may be helpful in promoting acceptance of follow-ons in Medicare but is not expected to result in near-term savings to the program.